[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,77,109,146,174,206,239],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100644489","think-find-solve-activities-for-insulin-self-management-in-type-1-diabetes-100644489",false,"NCT07670572","Think-Find-Solve Activities for Insulin Self-Management in Type 1 Diabetes","The Effect of Think-Find-Solve Activities on Insulin Self-Management in Children With Type 1 Diabetes: A Randomized Controlled Trial","Inclusion Criteria:\n\n* For the child:\n\nDiagnosed with Type 1 diabetes Aged between 8 and 12 years Able to read and write Able to understand and speak Turkish Diagnosed with diabetes for at least one year Regularly attending routine three-month outpatient clinic follow-ups Having no other diseases or medical conditions aside from diabetes The child agrees to participate in the study\n\n-For the Parent: Being the mother or father of the child with Type 1 diabetes Being the primary caregiver responsible for the child Able to read and write Agrees to participate in the study\n\nExclusion Criteria:\n\nThe child uses an insulin pump\n\n\\-","ALL","8 Years","12 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Children with type 1 diabetes require lifelong insulin therapy. However, improper management of insulin therapy may lead to serious, potentially life-threatening complications. The aim of this study is to examine the effect of an activity book developed for insulin therapy on insulin self-management among children with type 1 diabetes and their parents. The study is designed as a cluster randomized controlled experimental trial at the center level, including pre-test, 1- month, and 3-month follow-up measurements. The study will be initiated after obtaining ethical approval and institutional permissions. The sample will consist of children aged 8-12 years with type 1 diabetes and their parents. The study will be conducted in two different hospitals in Istanbul; using cluster randomization, one hospital will be assigned to the intervention group and the other to the control group. Prior to the main study, a pilot study will be conducted with 15 participants in each group, and the sample size will be calculated using G\\*Power based on the pilot data. Data will be collected using the \"Descriptive Information Form for Children with Diabetes\" and the \"Insulin Treatment Self-Management Scale (ITSMS) - Child (8-18 years) and Parent Forms.\" The \"Find-Solve-Learn Insulin Self-Management Activity Book\" will be applied to the children in the intervention group. The children will be monitored to complete the activity book at least twice a month for three months, and feedback will be obtained from their families regarding the process. The data collection process will include pre-test, 1-month, and 3-month follow-up measurements. The obtained data will be analyzed using appropriate statistical methods.",[27,28,29,30,31,32],"Type 1 Diabetes","Children","Activity","Insulin","Self Management","Parent",[34,35,36,37,38,39],"type 1 diabetes","children","activity","insulin","self management","parent","NOT_YET_RECRUITING","2026-06-25",{"date":43,"type":44},"2026-06-26","ACTUAL",{"date":46,"type":21},"2026-07-15",{"date":48,"type":21},"2027-06-15",{"name":50,"class":51},"Marmara University","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":16,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":52},"100629732","30-day-insulin-balance-metabolic-health-optimization-protocol-100629732","NCT07478497","30 Day Insulin Balance Metabolic Health Optimization Protocol","Inclusion Criteria:\n\n* Adults 18+ who are generally healthy\n* Ability to read and comprehend English\n* Ability to willfully consent and follow study procedures and tasks\n\nExclusion Criteria:\n\n* Individuals with Known Allergies\n* Pregnant or Nursing Individuals\n* Individuals with Insulin Disorders\n* Individuals with GI Disorders\n* Individuals with Mental Health Conditions\n* Individuals with Sleep Disorders\n* Individuals on Medication\n* Athletes under Specific Regulations\n* Individuals Sensitive to Fatigue",true,"18 Years",{"count":62,"type":21},100,[24],"Explore how a dietary supplement can help support healthy insulin levels and its impact on weight, fatigue, and sugar cravings. The Insulin Balance Formula and Hormetics Weight Optimization System is designed for people who are generally healthy and want to support and maintain healthy insulin levels to reach general health goals.",[30],"RECRUITING","2026-03-13",{"date":69,"type":44},"2026-03-17",{"date":71,"type":44},"2025-10-21",{"date":73,"type":21},"2026-10-21",{"name":75,"class":76},"Efforia, Inc","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":89,"conditions":90,"keywords":95,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":52},"100607292","phase-2-evaluation-of-a-novel-insulin-sensitizer-in-people-with-type-1-diabetes-100607292","NCT07186660","Evaluation of a Novel Insulin Sensitizer in People With Type 1 Diabetes","Evaluation of a Novel Insulin Sensitizer on Glycemic Control, Insulin Usage, and Cardiovascular Biomarkers in People With Type 1 Diabetes Who Use Closed-loop Automated Insulin Delivery","WBH003","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. History of type 1 diabetes for at least one year\n4. Age 18-45 years\n5. HbA1c \\\u003C10%\n\n   * BMI 18-35 kg\u002Fm2. Within this criterion, participants must have either BMI ≥25 or total daily insulin dose of ≥0.5 units\u002Fkg\u002Fday.\n   * Currently utilizing closed-loop AID therapy that is compatible with Dexcom G7 CGM.\n   * On stable regimen of non-diabetic medications for the last 6 months.\n   * All screening labs within normal limits or not clinically significant.\n   * Ability to take oral medication and be willing to adhere to the study drug\u002Fplacebo for 12 weeks.\n   * For females and males of reproductive potential: agreement to use adequate contraception during study participation and for an additional 2 weeks after the end of CIR-0602K administration.\n   * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner during study intervention.\n   * Agreement to adhere to Lifestyle Considerations throughout study duration.\n\nExclusion Criteria:\n\n* Current Pregnancy or currently breastfeeding.\n* History of smoking tobacco products within the last two years.\n* History of alcohol abuse or illicit drug abuse within 6 months of screening.\n* Known history of human immunodeficiency virus (HIV).\n* History of other significant disease (e.g., cardiac, cerebrovascular, gastrointestinal, liver, renal, or endocrine) that could, in the investigator's view, alter study outcomes\n* Any surgical or medical condition which may significantly alter the absorption of the study drug including but not limited to the following: history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, gastric bypass, gastric stapling, or gastric banding, currently active inflammatory bowel syndrome.\n* Current use of any antihyperglycemic medication beyond insulin (i.e., GLP-1 receptor agonists, SGLT2 inhibitors, etc.).\n* Unstable doses (i.e., dose change within the last 4 months) of vasoactive medications (e.g., calcium-channel blockers, statins, angiotensin-converting enzyme inhibitors, diuretics, nitrates, alpha-blockers, beta-blockers, etc.).\n* Daily use of anti-inflammatory medications (e.g., ibuprofen, aspirin, prednisone, dexamethasone, etc.).\n* Diagnosis of peripheral neuropathy (assessed by screening monofilament exam).\n* Macroalbuminuria (i.e., urine albumin: creatinine \\>300 mg per g).\n* Retinopathy beyond mild, nonproliferative retinopathy.\n* History of Level 3 hypoglycemia within the last 12 months.\n* History of diabetic ketoacidosis (DKA) within the last 12 months.\n* Screening electrocardiogram (ECG) findings indicative of arrhythmia, sinus node disease, or ischemic heart disease.\n* Screening oxygen saturation \\\u003C90%\n* History of hypersensitivity or prior adverse reaction to the study drug, closely-related compounds, or any of the stated ingredients.\n* Use of concomitant medications with a known significant metabolism by CYP2C8 or CYP2C (including paclitaxel, phenytoin, warfarin, celecoxib, tolbutamide, or repaglinide) for the duration of the study.\n* Participation in an investigational study (other than a non-treatment registry study) or received an investigational drug withing 30 days or 5 half-lives (whichever is longer) prior to randomization.","45 Years",{"count":20,"type":21},[88],"PHASE2","The purpose of this study is to see if the study drug CIR-0602K will improve glucose time-in-range and\u002For lower total daily insulin dose in people with type 1 diabetes who are using closed-loop automated insulin delivery. Researchers will compare CIR-0602K to a placebo (a look-alike substance that contains no drug) to see if it achieves the investigational endpoints. If the study results show that the drug works to increase time-in-range and lower insulin doses, this will lead to further studies which may then make the drug available to the public.",[91,92,30,93,94],"Type 1 Diabetes (T1D)","Glycemic Control for Diabetes Mellitus","Ketones","Cardiovascular Health",[27,96,97,98,99],"closed loop technology","time-in-range","adjunct therapy","cardiovascular health","2026-02-23",{"date":102,"type":44},"2026-02-25",{"date":104,"type":44},"2026-02-22",{"date":106,"type":21},"2028-09",{"name":108,"class":51},"University of Virginia",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":116,"minAge":60,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":22,"phases":120,"briefSummary":121,"conditions":122,"keywords":127,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":52},"100605654","injection-ports-vs-single-use-needles-for-insulin-in-pregnancy-effects-on-adherence-and-satisfaction-100605654","NCT07165327","Injection Ports vs Single-Use Needles for Insulin in Pregnancy: Effects on Adherence and Satisfaction","Injection Ports Versus Single-Use Needles for Insulin Administration in Diabetic Pregnancies: Impact on Dose Adherence and Patient Satisfaction","Inclusion Criteria:\n\n* Patients with type 2 diabetes mellitus or gestational diabetes who require a multi-dose insulin regimen\n\nExclusion Criteria:\n\n* T1DM, primary language non-English or Spanish, use of an insulin pump","FEMALE","50 Years",{"count":119,"type":21},44,[24],"This study wants to find out if using an injection port to give insulin during pregnancy helps people take their insulin more regularly and feel better about their care.\n\nWhen someone has diabetes during pregnancy, it's very important to keep their blood sugar levels in a healthy range. This usually means checking blood sugar often and giving insulin through shots. But giving many shots each day can be hard and uncomfortable.\n\nAn injection port is a small device placed on the skin that lets patients give insulin through the same spot without poking themselves each time. This may make taking insulin easier and less painful.\n\nFeeling comfortable with how insulin is given may help people stick to their treatment plan and have better health during pregnancy. Injection ports have already helped other patients, including pregnant people who needed other medications, but they haven't been studied for insulin use during pregnancy. This study will look at how pregnant patients with diabetes feel about using injection ports for insulin.",[123,124,125,126,30],"Gestatiaonl Diabetes Mellitus","Pregnancy","Diabetes in Pregnancy","Insulin Dependent Diabetes Mellitus",[128,129,130,131,132,133,134,135,136],"Gestational diabetes","Type 2 diabetes in pregnancy","Insulin administration","Injection port","Single-use needles","Dose adherence","Patient satisfaction","Insulin delivery devices","Pregnancy diabetes management","2025-09-02",{"date":139,"type":44},"2025-09-10",{"date":141,"type":21},"2025-10",{"date":143,"type":21},"2026-10",{"name":145,"class":51},"University of Texas at Austin",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":59,"sex":16,"minAge":60,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":22,"phases":157,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":52},"100512893","assessing-the-value-of-avocados-on-glycemic-control-in-type-2-diabetes-100512893","NCT05958368","Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes","The Effects of Hass Avocados on Glycemic Control in Persons With Type 2 Diabetes: A Randomized Controlled Crossover Trial","AVOCADO-T2D","Inclusion Criteria:\n\n* Participant reported diagnosis of Type 2 diabetes\n* HbA1c between 5.7%-11% (inclusive) and \u002F or fasting blood glucose of ≥ 100 mg\u002FdL\n* BMI 27-50 kg\u002Fm2 (inclusive)\n* Age range - 18 - 65 years (inclusive)\n* On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)\n* Willing to follow all requirements of study protocol including blood draws\n* Under the care of a physician who will be responsible for managing the subject's diabetes\n* Willing to give release to provide their treating MD with information about the trial\n\nExclusion Criteria:\n\n* Not willing or unable to consume study foods including avocados\n* Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months\n* Taking prescription or OTC weight loss medications within last 4 weeks\n* History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)\n* History of major surgery within three months of enrollment\n* Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)\n* Renal insufficiency consisting of potassium over 5.5 (mmol\u002FL) on a non-hemolyzed specimen, or a creatinine over 2.5 mg\u002FdL\n* Bilirubin over 3 (mg\u002FdL) or an albumin less than 3 (g\u002FdL)\n* ALT \\> 3 (IU\u002FL) times the upper limit of normal (normal range is 7-56)\n* Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.\n* Those on higher doses of diuretics (furosemide 40mg or higher or comparable)\n* Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)\n* Presence of implanted cardiac defibrillator\n* Blood pressure ≥180\u002F100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.\n* Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable\n* Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease\n* Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.\n* Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year)\n* Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control\n* Currently consuming \\>14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation\n* Participation in another clinical trial within 30 days prior to enrollment\n* Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial","65 Years",{"count":156,"type":21},48,[24],"The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.",[160,30,161,162,163,164],"Diabetes Mellitus, Type 2","Fructosamine","C-Reactive Protein","Glucose","Overweight and Obesity","2025-07-28",{"date":167,"type":44},"2025-07-31",{"date":169,"type":44},"2023-10-10",{"date":171,"type":21},"2026-12-15",{"name":173,"class":51},"Pennington Biomedical Research Center",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":16,"minAge":181,"maxAge":182,"enrollmentInfo":183,"targetDuration":185,"studyType":186,"phases":4,"briefSummary":187,"conditions":188,"keywords":192,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":52},"100583349","semi-closed-loop-automated-insulin-therapy-in-the-pediatric-population-aged-2-6-years-with-type-1-diabetes-impact-on-quality-of-life-and-glycemic-control-100583349","NCT06875167","Semi-closed Loop Automated Insulin Therapy in the Pediatric Population Aged 2-6 Years With Type 1 Diabetes: Impact on Quality of Life and Glycemic Control","Diablife","Inclusion Criteria:\n\n* -Patients aged 2 to 6 years inclusive\n* Presenting type 1 diabetes on insulin therapy\n* Social security affiliates\n* Patient initiating semi-closed loop treatment\n* Family (at least one parent or representative of parental authority) agreeing to follow the training necessary for continuous measurement of glucose in real time.\n* collection of non-opposition from one of the two parents or the representative of parental authority agreement\n\nExclusion Criteria:\n\n* Opposition to participation in research involving humans or opposition to the use of data or samples and associated data (withdrawal of non-opposition).","2 Years","6 Years",{"count":184,"type":21},20,"6 Months","OBSERVATIONAL","The incidence of type 1 diabetes is increasing, with an incidence of +4% per year in France today.\n\nThe treatment for type 1 diabetes is insulin therapy. In recent years, new systems have emerged, so-called \"semi-closed loop\" systems, also called automated insulin therapy, which have proven their superiority in terms of quality of life and glycemic balance in adults and children over 6 years old.\n\nSince January 24, 2024, the HAS now recognizes the indication of the semi-closed loop for the YPSOPUMP model in children aged 2 to 6 years. This is the first reimbursement in France of a closed loop system for the 2-6 year old age group. There are currently few studies comparing the quality of life of children in semi-closed loop versus other treatments (open loop or injections). Regarding quality of life, the studies found mainly concern the contribution for parents and the improvement of adolescents' sleep as in the study by Erin C Cobry et al from 2020 (6).\n\nOur study therefore aims to demonstrate an improvement in quality of life but also in diabetes balance in type 1 diabetic patients on a closed loop insulin pump versus open loop or injections in the pediatric population aged 2-6 years.",[27,189,30,190,191],"Closed Loop","Quality of Life","Pediatric",[193,194,195,196],"Closed-loop insulin therapy","type 1 Diabetic","Quality of life","pediatric patient","2025-04-16",{"date":199,"type":44},"2025-04-20",{"date":201,"type":44},"2025-03-17",{"date":203,"type":21},"2026-12",{"name":205,"class":51},"Fondation Lenval",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":213,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":22,"phases":216,"briefSummary":217,"conditions":218,"keywords":224,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":52},"100576842","music-effect-on-the-self-injection-testing-fear-and-pain-100576842","NCT06790550","Music Effect on the Self-Injection, Testing Fear and Pain","Examination of Music's Demonstration to Self-Injection, Fear of Testing and Pain in Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Type 2 diabetes for at least one year\n* Self-administering insulin injection\n* Self-administering glucometer, insulin pen or insulin pump\n\nExclusion Criteria:\n\n* poor mental health\n* Having gestational diabetes mellitus or Type 1 diabetes\n* no hearing problems","15 Years","75 Years",{"count":62,"type":21},[24],"Diabetes is a chronic and broad-spectrum metabolic disorder characterized by hyperglycemia that occurs due to relative or absolute insulin deficiency or \"insulin resistance\" developed against insulin action in peripheral tissues, affecting many organs and causing multisystem involvement. Metabolic function continues to deteriorate after diagnosis, leading to worsening glycemic control and insulin therapy becoming necessary. However, patients may have difficulty adhering to insulin therapy. Fears about injections are common in both adults and children and, as research shows, are a major reason why people with diabetes avoid taking insulin. Addressing these fears is an important part of helping patients reduce their risk of diabetes-related complications. Helping patients manage their replacement pain may help reduce the effects of needle fear in the future. There are a number of strategies that can ease the pain.The use of music in pain management has advantages such as being reliable, cheap, and having no side effects, as well as reducing postoperative pain reports. Music distracts the individual from negative stimuli and allows them to focus on something they enjoy, thus reducing pain and anxiety. Music therapy has also been shown to have sedative-protective effects and reduce stress hormone levels. Listening to preferred music can distract and reduce the pain and negative emotions associated with an unpleasant experience.",[219,30,220,221,222,223],"Type 2 Diabetes Mellitus (T2DM)","Fear","Pain","Injection","Music Therapy",[225,30,226,227,228,229],"type 2 diabetes mellitus","fear","pain","insulin injection","music","2025-01-24",{"date":232,"type":44},"2025-01-28",{"date":234,"type":21},"2025-01-30",{"date":236,"type":21},"2025-07-30",{"name":238,"class":51},"Dicle University",{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":247,"briefSummary":248,"conditions":249,"keywords":251,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":52},"100517725","microneedling-with-regular-insulin-versus-microneedling-alone-in-treatment-of-atrophic-scars-100517725","NCT06021275","Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars","Inclusion Criteria:\n\n1. Patients aged 12 to 60 years\n2. Atrophic scars (traumatic or surgical)\n3. Completely healed scars\n\nExclusion Criteria:\n\n1. Patients with a tendency or history of hypertrophic or keloidal scars\n2. Patients who received treatment for their scar in the past 3 months\n3. Diabetic patients or those with a history of Dysglycemia\n4. Pregnant, or lactating females\n5. Patients with active infection at the site of scar\n6. Patients currently receiving isotretinoin treatment or in the past month","60 Years",{"count":20,"type":21},[24],"Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.",[250,30],"Scars",[30,252],"scars","2024-07-27",{"date":255,"type":44},"2024-07-30",{"date":257,"type":44},"2023-10-01",{"date":259,"type":21},"2024-12",{"name":261,"class":51},"Alexandria University"]